GC Cell's immunotherapy trial for glioblastoma approved
GC Cell received approval for a clinical trial combining standard therapy with its immunotherapy Immuncell-LC for newly diagnosed glioblastoma patients. The 36-month study will evaluate safety and efficacy.
GC Cell selected for advanced regenerative medicine clinical research support project
GC Cell's HER2-targeted CAR-NK cell therapy for solid tumors selected for national advanced regenerative medicine clinical research support project, receiving 1.4 billion won funding for 21-month study.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.